首页> 美国卫生研究院文献>Frontiers in Immunology >Tolerance in Organ Transplantation: From Conventional Immunosuppression to Extracellular Vesicles
【2h】

Tolerance in Organ Transplantation: From Conventional Immunosuppression to Extracellular Vesicles

机译:器官移植的耐受性:从常规的免疫抑制到细胞外囊泡

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Organ transplantation is often the unique solution for organ failure. However, rejection is still an unsolved problem. Although acute rejection is well controlled, the chronic use of immunosuppressive drugs for allograft acceptance causes numerous side effects in the recipient and do not prevent chronic allograft dysfunction. Different alternative therapies have been proposed to replace the classical treatment for allograft rejection. The alternative therapies are mainly based in pre-infusions of different types of regulatory cells, including DCs, MSCs, and Tregs. Nevertheless, these approaches lack full efficiency and have many problems related to availability and applicability. In this context, the use of extracellular vesicles, and in particular exosomes, may represent a cell-free alternative approach in inducing transplant tolerance and survival. Preliminary approaches in vitro and in vivo have demonstrated the efficient alloantigen presentation and immunomodulation abilities of exosomes, leading to alloantigen-specific tolerance and allograft acceptance in rodent models. Donor exosomes have been used alone, processed by recipient antigen-presenting cells, or administered together with suboptimal doses of immunosuppressive drugs, achieving specific allograft tolerance and infinite transplant survival. In this review, we gathered the latest exosome-based strategies for graft acceptance and discuss the tolerance mechanisms involved in organ tolerance mediated by the administration of exosomes. We will also deal with the feasibility and difficulties that arise from the application of this strategy into the clinic.
机译:器官移植通常是器官衰竭的独特解决方案。但是,拒绝仍然是一个未解决的问题。尽管可以很好地控制急性排斥反应,但长期使用免疫抑制药物接受同种异体移植会在受体中引起许多副作用,并且不能预防慢性同种异体移植功能障碍。已经提出了不同的替代疗法来代替同种异体移植排斥的经典疗法。替代疗法主要基于不同类型的调节细胞(包括DC,MSC和Treg)的预输注。然而,这些方法缺乏充分的效率,并且存在许多与可用性和适用性有关的问题。在这种情况下,使用细胞外囊泡,特别是外来体,可以代表诱导移植耐受性和存活的无细胞替代方法。体外和体内的初步方法已经证明了外泌体的有效同种抗原呈递和免疫调节能力,从而在啮齿动物模型中导致了同种抗原特异性耐受性和同种异体移植物的接受。供体外泌体已单独使用,由受体抗原呈递细胞加工而成,或与次优剂量的免疫抑制药物一起使用,可实现特定的同种异体移植耐受性和无限的移植存活率。在这篇综述中,我们收集了最新的基于外泌体的移植物接受策略,并讨论了通过外泌体介导的器官耐受所涉及的耐受机制。我们还将处理这种策略在临床中的应用所带来的可行性和困难。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号